[225]Actinium-PSMA Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
Lancet Oncol 2024 Jan 10;[EPub Ahead of Print], MM Sathekge, IO Lawal, C Bal, F Bruchertseifer, S Ballal, G Cardaci, C Davis, M Eiber, T Hekimsoy, O Knoesen, C Kratochwil, NP Lenzo, J Mahapane, LC Maserumule, AH Mdlophane, KMG Mokoala, H Ndlovu, V Pant, H Rathke, J Reed, IB Sen, A Singh, A Sood, R Tauber, P Thakral, MP Yadav, A MorgensternFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.